SCHEMBL3390446

SCHEMBL3390446

Brc1cc(Br)cc(-c2cc(-c3ccccn3)nc(-c3cccc(Br)n3)c2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.55
SMN1; SMN2 Q16637 6/20 0.55
LMNA P02545 5/20 0.55
TP53 P04637 5/20 0.55
CCR1 P32246 3/20 0.55
CCR5 P51681 3/20 0.55
CCR8 P51685 3/20 0.55
ALOX15 P16050 2/20 0.55
HTT P42858 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
ALPL P05186 1/20 0.55
HSP90AA1 P07900 1/20 0.55
ALPI P09923 1/20 0.55
ALPG P10696 1/20 0.55
MAPK1 P28482 1/20 0.55
GRM5 P41594 5/20 0.46
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42
METAP1 P53582 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15249622 0.91 SMN1; SMN2 (0.58) KDM4ESMN1; SMN2LMNATP53CCR1
SCHEMBL12257971 0.91 SMN1; SMN2 (0.58) KDM4ESMN1; SMN2LMNATP53CCR1
SCHEMBL30781630 0.91 CCR1 (0.56) KDM4ESMN1; SMN2LMNATP53CCR1
SCHEMBL3392425 0.90 KDM4E (0.53) KDM4ESMN1; SMN2LMNATP53CCR1
SCHEMBL14243601 0.85 KDM4E (0.64) KDM4ESMN1; SMN2LMNATP53CCR1
SCHEMBL3392131 0.85 KDM4E (0.51) KDM4ESMN1; SMN2LMNATP53CCR1
SCHEMBL994004 0.85 KDM4E (0.75) KDM4ESMN1; SMN2LMNATP53CCR1
SCHEMBL16451455 0.83 KDM4E (0.78) KDM4ESMN1; SMN2LMNATP53CCR1
SCHEMBL353379 0.83 KDM4E (0.71) KDM4ESMN1; SMN2LMNATP53CCR1
SCHEMBL14297308 0.83 KDM4E (0.78) KDM4ESMN1; SMN2LMNATP53CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2246351-B1 COMPOUND HAVING PYRIDOINDOLE RING STRUCTURE BONDED WITH SUBSTITUTED PYRIDYL GROUP, AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO LTD (JP) 2015-05-06 EP disclosed
US-8624228-B2 Compound having pyridoindole ring structure bonded with substituted pyridyl group, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2014-01-07 US disclosed
US-20100308322-A1 COMPOUND HAVING PYRIDOINDOLE RING STRUCTURE BONDED WITH SUBSTITUTED PYRIDYL GROUP, AND ORGANIC ELECTROLUMINESCENT DEVICE Hodogaya Chemical Co,. Ltd. (JP) 2010-12-09 US disclosed
EP-2246351-A1 COMPOUND HAVING PYRIDOINDOLE RING STRUCTURE BONDED WITH SUBSTITUTED PYRIDYL GROUP, AND ORGANIC ELECTROLUMINESCENT DEVICE Hodogaya Chemical Co., Ltd. (JP) 2010-11-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100308322-A1 COMPOUND HAVING PYRIDOINDOLE RING STRUCTURE BONDED WITH SUBSTITUTED PYRIDYL GROUP, AND ORGANIC ELECTROLUMINESCENT DEVICE KCNH3, KCNH2, PRDM9 KDM4E 1240/4885SMN1; SMN2 3209/4885LMNA 2167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.